Analytical Data
-
基因名
IFNL1
- Application
-
别名
IFNL1；IL29；ZCYTO21；Interferon lambda-1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8IU54
-
表达区间
20-200aa
-
氨基酸序列
GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T
-
分子量
19.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFNL1, also known as Interferon Lambda 1, is a member of the type III interferon family, which plays a crucial role in the immune response against viral infections. Its significance has gained attention due to its ability to modulate immune responses in various tissues, particularly in the liver and mucosal surfaces. IFNL1 exerts its effects through binding to the IFNLR1 receptor, activating signaling pathways that lead to the expression of antiviral genes and an enhancement of innate immunity. Research has shown that polymorphisms in the IFNL1 gene can influence susceptibility to viral infections, such as hepatitis C, and impact patient response to antiviral therapies. Furthermore, emerging studies are exploring the potential therapeutic applications of IFNL1 in treating a range of diseases, including viral infections, autoimmune disorders, and cancers. The understanding of IFNL1's biological functions and its role in the immune system has positioned it as a promising target for drug development, paving the way for new antiviral strategies and immunotherapies. As research progresses, the characterization of IFNL1 and its recombinant forms holds the potential to enhance our approach to managing infectious diseases and improving clinical outcomes in affected patients.
